Zuclopenthixol decanoate - Schizophrenia and other psychoses
You are here : Home > Formulary Search > Zuclopenthixol decanoate - Schizophrenia and other psychoses
Status 1
- Depot injection
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
PAD Profile
Other Indications
Below are listed other indications that Zuclopenthixol decanoate is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Schizophrenia and other psychoses.
Committee Recommendations (1)
The Surrey Heartlands APC recommends the administration of depot antipsychotic injections under an AMBER shared care agreement for practices that have signed up to the agreed locally commissioned service (LCS).
The updated shared care agreement can be found below.
Surrey Heartlands CCG have developed the LCS to enable stable patients with schizophrenia to be prescribed and administered these injections through their primary care prescriber (GP).
If a practice has not signed up to the LCS the drug remains as RED status and prescriptions will be issued by the provider.
Note: Clopixol Acuphase is an intermediate-acting formulation of zuclopenthixol acetate which should only be used on in-patient units for the short-term management of acute psychotic episodes and mania. When prescribing intramuscular zuclopenthixol, check that the prescription is clear and unambiguous in order to ensure the intended treatment is dispensed and administered